NEW YORK (Reuters Health)—Risankizumab, an inhibitor of interleukin (IL) 23, provides some relief for patients with active psoriatic arthritis (PsA) whose symptoms have responded poorly to standard treatments, according to 24-week results of a phase-3 trial. “Despite the range of available therapies for psoriatic arthritis, efficacious, well-tolerated therapeutic options are needed to treat the diverse…
Search results for: nail psoriasis
Guselkumab Boosts Response in Resistant Psoriatic Arthritis
NEW YORK (Reuters Health)—In patients with psoriatic arthritis (PsA) who are resistant to tumor necrosis factor inhibitors (TNFi), guselkumab was more effective than placebo in a phase 3b trial. “Guselkumab is a relatively new treatment and is the first drug in its class (IL-23 inhibitor) to gain approval for PsA,” Dr. Laura Coates of the…
Secukinumab Effective Across the Spectrum of Psoriatic Arthritis
A posthoc analysis confirms patients with active psoriatic arthritis (PsA) taking secukinumab experience improvement in all signs and symptoms of PsA as measured by the GRAPPA-OMERACT disease activity core domains.
Case Report: A Psoriatic Arthritis Patient with Dactylitis & Enthesitis
A 36-year-old woman presented at the Johns Hopkins Arthritis Center for a second opinion regarding a diagnosis of psoriatic arthritis (PsA). One year prior to our evaluation, she had developed pain and stiffness in her hands, feet, knees, ankles, elbows and shoulders. She had mild plaque psoriasis of the scalp and base of the neck,…
Where Viral Infections Meet Rheumatic Disease
SAN DIEGO—Viral infections are a common cause of acute arthritis and, in general, tend to be short lived and are not usually associated with significant articular inflammation. Due to the prevalence of various viral infections across the globe, any patient with signs of early inflammatory arthritis (i.e., symptoms that have not yet lasted six weeks) should be evaluated for a possible infectious etiology, said Dr. Leonard Calabrese in the Review Course at ACR Convergence 2023.
The Heterogeneity of Psoriatic Arthritis
SAN DIEGO—Differences between psoriatic arthritis and rheumatoid arthritis highlight the need for the development of imaging modalities, laboratory tests and other biomarkers that are explored and validated specifically for PsA to advance the goal of personalized or precision medicine. In this article, expert David S. Pisetsky, MD, PhD, explores the top research in psoriatic arthritis presented at ACR Convergence 2023.
Case Report: Hajdu-Cheney Syndrome
Hajdu-Cheney syndrome (HCS) is a rare connective tissue disease, with fewer than 100 cases reported worldwide.1 Hallmark features include acro-osteolysis (i.e., resorption of the distal phalanges of the hands and feet), osteoporosis, facial dysmorphisms, and craniofacial and dental abnormalities. Patients often have short stature and can have neuroanatomical deformities causing intellectual disabilities. These patients can…
Speak Out Rheum: Musings on Our Past & Rheumatology
I have been reading Yuval Harari’s thought-provoking and engaging book, Sapiens: A Brief History of Humankind, about our species’ struggles and the path that led to our emergence as the predominant species. I was captivated by the drawing of the hand of one of our ancestors and mused about what that forebear was thinking as…
A Look Back at the First Use of Cortisone in Rheumatoid Arthritis
In 1949, the first description of patients with rheumatoid arthritis (RA) given cortisone sent shockwaves through the medical community, quickly capturing the public imagination as well. The paradigm-shifting report paved the way for the use of cortisone and related drugs in RA and many other medical conditions.1 The following is a discussion of some of…
The 2022 ACR Awards of Distinction
During ACR Convergence 2022 in early November, the ACR honored a group of individuals who have made significant contributions to rheumatology research, education and patient care by announcing the recipients of the ACR’s 2022 Awards of Distinction, as well as the 2022 ACR Masters, recognized for their contributions to the field. See the November issue…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 7
- Next Page »